<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795063</url>
  </required_header>
  <id_info>
    <org_study_id>FUGES-022</org_study_id>
    <nct_id>NCT04795063</nct_id>
  </id_info>
  <brief_title>Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer</brief_title>
  <official_title>Randomized Controlled Trials on Clinical Outcomes of Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical efficacy (safety, feasibility and long-term efficacy) of total&#xD;
      robotic versus robotic assisted distal gastrectomy for patients with gastric cancer (cT1-4a,&#xD;
      N0/+, M0).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the field of gastrectomy, Hashizume et al. first reported robotic gastrectomy in 2002.&#xD;
      Since then, reports on the safety and feasibility of the application of robotic surgical&#xD;
      system in the treatment of gastric cancer (GC) have gradually increased. Reports of robotic&#xD;
      surgery for GC are increasing, especially in Asia. Several studies confirmed the advantages&#xD;
      of robotic gastrectomy when compared with laparoscopic gastrectomy. However, whether total&#xD;
      robotic gastrectomy is noninferior to robotic-assisted gastrectomy remains unclear. The&#xD;
      investigator first carried out this study in the world to evaluate the efficacy of total&#xD;
      robotic versus robotic assisted distal gastrectomy for GC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity rates</measure>
    <time_frame>30 days</time_frame>
    <description>This is for the early postoperative complication, which defined as the event observed within 30 days after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>3-year disease free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>3-year overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year recurrence pattern</measure>
    <time_frame>36 months</time_frame>
    <description>Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative morbidity rates</measure>
    <time_frame>1 day</time_frame>
    <description>The intraoperative postoperative morbidity rates are defined as the rates of event observed within operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall postoperative serious morbidity rates</measure>
    <time_frame>30 days</time_frame>
    <description>Refers to the incidence of early postoperative complication which is graded as Clavien-Dindo IIIA or higher</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Retrieved Lymph Nodes</measure>
    <time_frame>1 day</time_frame>
    <description>Total Number of Retrieved Lymph Nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative recovery course</measure>
    <time_frame>30 days</time_frame>
    <description>Duration of postoperative hospital stay in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative nutritional status</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
    <description>The variation of weight on postoperative 3, 6, 9 and 12 months are used to access the postoperative nutritional status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory immune response</measure>
    <time_frame>Preoperative 3 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The variation of white blood cell count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of digestive tract reconstruction</measure>
    <time_frame>1 day</time_frame>
    <description>From the beginning to the end of digestive tract reconstruction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Robotic Gastrectomy</condition>
  <arm_group>
    <arm_group_label>Total Robotic Distal Gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After exploration and randomization, patients received total robotic distal gastrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Robotic-Assisted Distal Gastrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After exploration and randomization, patients received robotic-assisted distal gastrectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Robotic Distal Gastrectomy</intervention_name>
    <description>All the surgical procedures are performed using the robot system.</description>
    <arm_group_label>Total Robotic Distal Gastrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robotic-Assisted Distal Gastrectomy</intervention_name>
    <description>After finishing the lymphadenectomy, the digestive tract reconstruction is performed extracorporal.</description>
    <arm_group_label>Robotic-Assisted Distal Gastrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from over 18 to under 75 years&#xD;
&#xD;
          2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or&#xD;
             poorly differentiated) confirmed pathologically by endoscopic biopsy&#xD;
&#xD;
          3. cT1-4a (clinical stage tumor), N-/+, M0 at preoperative evaluation according to the&#xD;
             American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition&#xD;
&#xD;
          4. expected to perform distal gastrectomy with D1+/D2 lymph node dissection to obtain R0&#xD;
             resection surgicall results.&#xD;
&#xD;
          5. Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale&#xD;
&#xD;
          6. American Society of Anesthesiology (ASA) class I to III&#xD;
&#xD;
          7. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women during pregnancy or breast-feeding&#xD;
&#xD;
          2. Severe mental disorder&#xD;
&#xD;
          3. History of previous upper abdominal surgery (except laparoscopic cholecystectomy)&#xD;
&#xD;
          4. History of previous gastric surgery (except Endoscopic Submucosal&#xD;
             Dissection/Endoscopic Mucosal Resection (ESD/EMR) for gastric cancer)&#xD;
&#xD;
          5. Gastric multiple primary carcinoma&#xD;
&#xD;
          6. Enlarged or bulky regional lymph node （diameter over 3cm）supported by preoperative&#xD;
             imaging&#xD;
&#xD;
          7. History of other malignant disease within the past 5 years&#xD;
&#xD;
          8. History of previous neoadjuvant chemotherapy or radiotherapy&#xD;
&#xD;
          9. History of unstable angina or myocardial infarction within the past 6 months&#xD;
&#xD;
         10. History of cerebrovascular accident within the past 6 months&#xD;
&#xD;
         11. History of continuous systematic administration of corticosteroids within 1 month&#xD;
&#xD;
         12. Requirement of simultaneous surgery for other disease&#xD;
&#xD;
         13. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by&#xD;
             gastric cancer&#xD;
&#xD;
         14. Forced expiratory volume in 1 second (FEV1)&lt;50% of the predicted values&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang-ming Huang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fujian Medical University Union Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang-ming Huang, MD</last_name>
    <phone>+86-13805069676</phone>
    <email>hcmlr2002@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qi-yue Chen, PhD</last_name>
    <phone>+86-15980235636</phone>
    <email>690934662@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Changming Huang, M.D., Ph.D.</last_name>
      <phone>+86-133-6591-0253</phone>
      <email>hcmlr2002@163.com</email>
    </contact>
    <investigator>
      <last_name>Changming Huang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Chang-Ming Huang, Prof.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>robotic assisted distal gastrectomy</keyword>
  <keyword>total robotic distal gastrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

